AI assistant
MetaVia Inc. — Director's Dealing 2016
Aug 5, 2016
34919_dirs_2016-08-04_182d3c03-5c88-4394-8142-fee616745841.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2016-08-04
Reporting Person: Bisgaier Charles PhD (Director, Chair & Chief Scientific Off., 10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1192690 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $1.344 | 2025-06-28 | Common Stock (4474) | Direct | |
| Series A Convertible Preferred Stock | $ | Common Stock (59561) | Indirect | ||
| 8% Convertible Subordinated Promissory Notes | $6.7059 | Common Stock () | Indirect | ||
| 8% Convertible Subordinated Promissory Notes | $6.7059 | Common Stock () | Indirect |
Footnotes
F1: The Series A Convertible Preferred Stock has no expiration date, and shall convert into shares of common stock, par value $0.001 per share, of Gemphire Therapeutics Inc. (the "Company") on a one-for-one basis immediately prior to the closing of the Company's initial public offering.
F2: These shares are indirectly owned by the reporting person as trustee of The Charles L. Bisgaier Trust.
F3: The notes were issued in the original principal amount of $125,000. The outstanding principal and accrued interest on such notes will automatically convert into shares of common stock, par value $0.001 per share, of the Company immediately prior to the closing of the Company's initial public offering. The notes bear interest at a rate of 8% per annum. The notes have accrued interest of $3,781 to date and will continue to accrue interest until conversion.
F4: The notes were issued in the original principal amount of $100,000. The outstanding principal and accrued interest on such notes will automatically convert into shares of common stock, par value $0.001 per share, of the Company immediately prior to the closing of the Company's initial public offering. The notes bear interest at a rate of 8% per annum. The notes have accrued interest of $8,132 to date and will continue to accrue interest until conversion.